Dashboard
Manage Tickers

MRUSMerus N.V.

Nasdaq merus.nl


$ 43.94 $ -1.32 (-2.92 %)    

Friday, 10-May-2024 11:14:44 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.53 $ -1.39 (-0.31 %)
DIA $ 394.70 $ -0.56 (-0.14 %)
SPY $ 520.40 $ -1.11 (-0.21 %)
TLT $ 90.07 $ -0.24 (-0.27 %)
GLD $ 218.46 $ -1.32 (-0.6 %)
$ 45.12
$ 45.26
$ 0.00 x 0
$ 0.00 x 0
$ 43.83 - $ 45.26
$ 19.81 - $ 52.04
560,987
na
2.62B
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-merus-maintains-65-price-target
HC Wainwright & Co. Reiterates Buy on Meru...
05/09/2024 11:28:51

HC Wainwright & Co. analyst Andrew Fein reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $65 price target.

merus-q1-eps-059-beats-081-estimate-sales-789m-miss-974m-estimate
Merus Q1 EPS $(0.59) Beats $(0.81) Estimat...
05/08/2024 22:35:42

Merus (NASDAQ:MRUS) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.81) by 27.1...

merus-announces-us-fda-acceptance-and-priority-review-of-bla-for-zeno-for-the-treatment-of-nrg1-nsclc-and-pdac
Merus Announces U.S. FDA Acceptance And Pr...
05/06/2024 20:28:37

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length...

needham-reiterates-buy-on-merus-maintains-66-price-target
Needham Reiterates Buy on Merus, Maintains...
04/11/2024 09:42:47

Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $66 price target.

merus-presents-preclinical-data-demonstrating-efficacy-of-zeno-in-cancer-models-with-high-nrg1-expression-at-the-aacr-annual-meeting-2024
Merus Presents Preclinical Data Demonstrat...
04/08/2024 16:03:11

Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology co...

truist-securities-initiates-coverage-on-merus-with-buy-rating-announces-price-target-of-69
Truist Securities Initiates Coverage On Me...
03/28/2024 15:34:22

Truist Securities analyst Asthika Goonewardene initiates coverage on Merus (NASDAQ:MRUS) with a Buy rating and announces Pri...

needham-maintains-buy-on-merus-raises-price-target-to-66
Needham Maintains Buy on Merus, Raises Pri...
03/07/2024 11:06:41

Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $65 to $66.

Core News & Articles
Gilead and Merus Announce Collaboration To...
03/06/2024 13:05:34

merus-announces-publication-of-abstract-for-presentation-at-aacr-annual-meeting-2024
Merus Announces Publication Of Abstract Fo...
03/05/2024 21:31:08

needham-maintains-buy-on-merus-raises-price-target-to-65
Needham Maintains Buy on Merus, Raises Pri...
03/04/2024 10:35:46

Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $42 to $65.

on-wednesday-february-28-2024-merus-reported-q4-adjusted-eps-109-misses-074-estimate-sales-894m-miss-1013m-estimate
On Wednesday February 28, 2024, Merus Repo...
02/29/2024 20:26:12

Merus (NASDAQ:MRUS) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47...

hc-wainwright--co-maintains-buy-on-merus-raises-price-target-to-65
HC Wainwright & Co. Maintains Buy on Merus...
02/29/2024 20:24:26

HC Wainwright & Co. analyst Andrew Fein maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $48 to...

stifel-maintains-buy-on-merus-raises-price-target-to-65
Stifel Maintains Buy on Merus, Raises Pric...
02/29/2024 17:43:44

Stifel analyst Bradley Canino maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $40 to $65.

bmo-capital-maintains-outperform-on-merus-raises-price-target-to-58
BMO Capital Maintains Outperform on Merus,...
02/29/2024 13:08:48

BMO Capital analyst Etzer Darout maintains Merus (NASDAQ:MRUS) with a Outperform and raises the price target from $49 to $58.

as-of-december-31-2023-merus-had-4117m-cash-cash-equivalents-and-marketable-securities
As Of December 31, 2023, Merus Had $411.7M...
02/28/2024 22:04:13

Cash Runway, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2027As of De...

needham-reiterates-buy-on-merus-maintains-42-price-target
Needham Reiterates Buy on Merus, Maintains...
12/04/2023 11:42:42

Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $42 price target.

merus-presented-updated-clinical-data-on-mcla-129-for-cancer-treatment-at-esmo-asia-2023
Merus Presented Updated Clinical Data On M...
12/04/2023 06:56:11

expert-ratings-for-merus
Expert Ratings for Merus
11/28/2023 12:00:18

needham-reiterates-buy-on-merus-maintains-42-price-target
Needham Reiterates Buy on Merus, Maintains...
11/28/2023 10:19:41

Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $42 price target.

merus-announces-publication-of-abstracts-on-mcla-129-for-presentation-at-esmo-asia-congress-2023
Merus Announces Publication Of Abstracts O...
11/27/2023 04:44:47

-  Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sun...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION